PriceTargets.com logo

Medifast - MED Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $110.50
  • Forecasted Upside: 34.77%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$81.99 As of 06/8/2023 01:00 AM ET
▼ -0.95 (-1.15%)

This chart shows the closing price for MED by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Medifast Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MED and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MED

Analyst Price Target is $110.50
▲ +34.77% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Medifast in the last 3 months. The average price target is $110.50, with a high forecast of $150.00 and a low forecast of $71.00. The average price target represents a 34.77% upside from the last price of $81.99.

This chart shows the closing price for MED for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 2 contributing investment analysts is to hold stock in Medifast. This rating has held steady since April 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/15/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/15/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/2/2023DA DavidsonLower Target$94.00 ➝ $71.00Low
2/22/2023DA DavidsonLower TargetNeutral$106.00 ➝ $94.00Low
11/4/2022DA DavidsonDowngradeBuy ➝ Neutral$278.00 ➝ $106.00Low
8/4/2022DA DavidsonLower TargetBuy$352.00 ➝ $278.00Low
8/4/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$345.00 ➝ $150.00Low
6/2/2022DA DavidsonBoost TargetBuy$341.00 ➝ $352.00High
2/24/2022DA DavidsonLower TargetBuy$349.00 ➝ $341.00Low
11/8/2021DA DavidsonLower TargetBuy$395.00 ➝ $349.00Medium
8/23/2021DA DavidsonReiterated RatingBuyC$395.00Medium
5/5/2021B. RileyBoost TargetBuy$310.00 ➝ $400.00Medium
5/5/2021DA DavidsonBoost TargetBuy$302.00 ➝ $395.00High
3/4/2021DA DavidsonBoost TargetBuy$239.00 ➝ $302.00N/A
2/26/2021DA DavidsonBoost TargetBuy$239.00 ➝ $302.00Low
2/26/2021B. RileyBoost TargetBuy$300.00 ➝ $310.00High
2/19/2021B. RileyBoost TargetBuy$250.00 ➝ $300.00Low
1/25/2021Jefferies Financial GroupUpgradeHold ➝ Buy$205.00 ➝ $265.00High
1/12/2021DA DavidsonBoost TargetPositive ➝ Buy$205.00 ➝ $239.00Medium
11/5/2020DA DavidsonUpgradeNeutral ➝ Buy$180.00 ➝ $205.00High
11/3/2020B. RileyBoost TargetBuy$230.00 ➝ $250.00High
10/9/2020B. RileyBoost Target$220.00 ➝ $230.00Medium
10/1/2020Jefferies Financial GroupUpgradeBuy$210.00Medium
8/10/2020DA DavidsonBoost TargetNeutral$86.00 ➝ $180.00Low
8/6/2020B. RileyBoost Target$164.00 ➝ $220.00Medium
6/25/2020B. RileyInitiated CoverageBuy$164.00High
5/6/2020DA DavidsonBoost TargetNeutral$83.00 ➝ $86.00High
2/27/2020DA DavidsonBoost TargetNeutral$74.00 ➝ $83.00High
2/27/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$130.00 ➝ $90.00High
1/14/2020Jefferies Financial GroupBoost TargetBuy$110.00 ➝ $130.00High
11/8/2019Dougherty & CoDowngradeBuy ➝ NeutralHigh
11/8/2019DA DavidsonDowngradeBuy ➝ Neutral$250.00 ➝ $74.00High
9/23/2019DA DavidsonSet TargetBuy$250.00Medium
9/13/2019DA DavidsonSet TargetBuy$250.00Low
7/25/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$130.00Medium
2/27/2019SidotiBoost TargetBuy ➝ Buy$211.00 ➝ $216.00High
11/8/2018SidotiUpgradeNeutral ➝ BuyMedium
8/3/2018DA DavidsonBoost TargetBuy$249.00Low
7/23/2018DA DavidsonBoost TargetBuy$201.00Medium
(Data available from 6/8/2018 forward)

News Sentiment Rating

0.70 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
11/10/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/10/2022
  • 5 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/9/2023
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/8/2023
  • 10 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
3/10/2023
  • 7 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/9/2023
  • 12 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2023
  • 9 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2023

Current Sentiment

  • 9 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Medifast logo
Medifast, Inc. engages in the provision of healthy living products and programs. It offers the OPTAVIA brand, a lifestyle solution centered on developing new healthy habits through smaller, foundational changes called micro-habits. The firm's product line includes bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. The company was founded by William Vitale in 1981 and is headquartered in Baltimore, MD.
Read More

Today's Range

Now: $81.99
Low: $80.83
High: $83.13

50 Day Range

MA: $90.68
Low: $78.69
High: $103.67

52 Week Range

Now: $81.99
Low: $77.67
High: $192.44

Volume

166,731 shs

Average Volume

207,748 shs

Market Capitalization

$892.87 million

P/E Ratio

6.42

Dividend Yield

8.06%

Beta

1.21

Frequently Asked Questions

What sell-side analysts currently cover shares of Medifast?

The following Wall Street research analysts have issued research reports on Medifast in the last twelve months: DA Davidson, Jefferies Financial Group Inc., StockNews.com, and TheStreet.
View the latest analyst ratings for MED.

What is the current price target for Medifast?

2 Wall Street analysts have set twelve-month price targets for Medifast in the last year. Their average twelve-month price target is $110.50, suggesting a possible upside of 36.3%. Jefferies Financial Group Inc. has the highest price target set, predicting MED will reach $150.00 in the next twelve months. DA Davidson has the lowest price target set, forecasting a price of $71.00 for Medifast in the next year.
View the latest price targets for MED.

What is the current consensus analyst rating for Medifast?

Medifast currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MED, but not buy more shares or sell existing shares.
View the latest ratings for MED.

What other companies compete with Medifast?

Other companies that are similar to Medifast include Utz Brands, Mission Produce, Arko, B&G Foods and SunOpta. Learn More about companies similar to Medifast.

How do I contact Medifast's investor relations team?

Medifast's physical mailing address is 100 International Drive, Baltimore MD, 21202. The specialty retailer's listed phone number is (410) 581-8042 and its investor relations email address is [email protected]. The official website for Medifast is www.medifast1.com. Learn More about contacing Medifast investor relations.